HOPE Against Cancer Recurrence in HCC

Liver transplantation is often performed to treat liver cancer, or hepatocellular carcinoma (HCC), in patients with impaired liver function due to cirrhosis. A shortcoming, however, is tumor recurrence after transplantation. Approximately 15 % of patients receiving livers develop recurrence and this depends on the quality of the liver received. Machine liver perfusion, for example, hypothermic oxygenated liver perfusion (HOPE), which means that the organ is perfused with an oxygen-rich fluid in a cold environment before transplantation, is a novel method to improve the quality of livers befor

Trial Details

NCT ID
NCT06717919
Phase
PHASE4
Sponsor
Philipp Dutkowski
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Hypothermic oxygenated perfusion
  • Conventional cold storage
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Innsbruck, Austria|47.26266,11.39454
  • Vienna, Austria|48.20849,16.37208
  • Leuven, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • Adult recipients (\>18y), listed for liver transplantation with documented HCC (Liver Imaging Reporting and Data System (LIRADS) 5 lesion in magnet…
  • within up to seven criteria, i.e. HCC with seven as the sum of the diameter of the largest tumour (in cm) and the number of tumours at the time poi…
  • written informed consent for the trial. This also includes patients beyond the up to seven criteria after successful downsizing of the HCC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →